A combination of Bristol-Myers Squibb’s Opdivo (nivolumab)and Yervoy (ipilimumab) has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
The firm said that the Phase III CheckMate-214 study missed one of its co-primary endpoints in that there was no significant difference in PFS in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma between the two treatment arms.
The data do show some improvement, however, with median PFS 11.56 months for the Opdivo and Yervoy combination versus 8.38 months for Sutent (sunitinib).
The combination also met the co-primary endpoint of objective response rate (ORR), and achieving a 41.6 percent ORR versus 26.5 percent for Sutent.
“We are encouraged by the totality of the CheckMate-214 data,” said Vicki Goodman, development lead, Melanoma and Genitourinary Cancers, BMS.
Read the full story on Pharmatimes here